Phase II trial data suggests ensovibep (MP0420) significantly reduces SARS-CoV-2 viral load and reduces hospitalisation and death due to COVID-19.
List view / Grid view
12 November 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Molecular Partners have entered into a strategic manufacturing collaboration...
29 June 2010 | By College Hill Ltd
Molecular Partners AG, announced today the appointment of Dr Göran Ando as independent non-executive member of the board of directors...